Low cost medicines & devices bring new lease of life
New Delhi, Oct 26: The Narendra Modi government has taken bold steps to offer affordable healthcare to common people of the country. The Modi government has walked the talk of 'Affordable, Quality Healthcare for All'.
Drugs Under Price Control:
Drug price regulator NPPA has fixed the ceiling price for 92 drug formulations, including those used for treatment of cancer, hepatitis C, migraine and diabetes among others.
The National Pharmaceutical Pricing Authority (NPPA) said while the retail price of 72 scheduled formulations has been fixed, that of 9 has been revised. Further, the authority has also revised the retail prices of 11 scheduled formulations.
"NPPA has fixed/revised ceiling prices/retail prices of 92 formulations under Drugs (Prices Control) Order, 2013," it said in a notification.
NPPA fixes the ceiling price of essential medicines of Schedule I under the Drugs (Prices Control) Order (DPCO) 2013. In respect of medicines that are not under price control, manufacturers are allowed to increase the maximum retail price by 10 per cent annually.
Janaushadhi Pariyojana:
As on 05.03.2018, under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), 3214 Kendras have been opened in 33 States/Union Territories of the Country and are functional in order to make available quality generic medicines at affordable prices to all. A State/UT-wise list of 3214 functional PMBJP Kendras, including in West Bengal, Gujarat, Kerala and Maharastra.
Under PMBJP, the product basket of the scheme now covers more than 700 medicines and 154 surgicals and consumables covering all major therapeutic groups such as Analgesics, Antipyretics, Anti-allergies, Anti-infectives, Anti-diabetic, Cardiovasculars, Anti-cancers, Gastro-intestinal medicines, Diuretics, etc. 666 medicines and 81 surgicals are available for supply under Pradhan Mantri Bhartiya Janaushadhi Priyojna.
Deregulating Stents:
Government
has
notified
the
ceiling
prices
of
Coronary
Stent
vide
notification
dated
13th
Feb
2017
at
Rs.
7,260
for
Bare
Metal
Stent(
BMS)
and
Rs
29,600
for
Drug
Eluting
Stent
(DES)
(including
BVS
and
Biodegradable
Stent).
After
accounting
for
WPI,
the
ceiling
prices
were
revised
to
Rs.
7,400
for
BMS
and
Rs.
30,180
for
DES
with
effect
from
1-4-2017.
As
per
data
provided
by
the
stent
Annual
Report
2017-18
102
manufacturers
and
importers
before
price
notification,
the
average
MRP
was
Rs.
45,100
for
BMS
and
Rs.
121,400
for
DES.
The
price
reduction
therefore
worked
out
to
85%
for
BMS
and
74%
for
DES.
The
fixation
of
ceiling
price
of
coronary
stents
enabled
the
annual
saving
of
Rs.
4,450
crores
to
the
public.
Knee plants
Based on the numbers of about 1 to 1.5 lakh orthopaedic knee procedures done in India every year, there will be a saving of about Rs.1500 crore for the people of India per annum. It is a step to prevent Unethical Profiteering and ensure Affordable and Quality Healthcare for the Last Man.
Type of Knee Implant | Average MRP Earlier(Rupees) | Average Price Reduction | New Ceiling Price and MRP*(Rupees) |
Cobalt Chromium (most widely used) | 1,58,324 | 65% | 54,720 |
Special Metal like Titanium & Oxidized Zirconium | 2,49,251 | 69% | 76,600 |
High Flexibility Implant | 1,81,728 | 69% | 56,490 |
Revision Implants | 2,76,869 | 59% | 1,13,950 |
Specialised Implants for Cancer & Tumour | Company specific prices; to be fixed by NPPA at Rs. 1,13,950 |
Read in Telugu: ఔషధ ధరల నియంత్రణతో సామాన్యుడి ఆరోగ్యానికి భరోసా ఇచ్చిన మోడీ